spacer
home > pmps > spring 2007 > readability testing – a bitter ‘pil’ to swallow?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Readability Testing – A Bitter ‘Pil’ to Swallow?

Sophie Hobson at TRAC Services examines the processes fundamental to adapting patient information leaflets (PIL) in time for the July 2008 deadline

With less than 14 months before all patient information leaflets (PIL) in the UK have to comply with mandatory readability requirements, as set out in Article 59(3) of Directive 2004/27/EC, the question of whether pharmaceutical manufacturers are on target to meet the deadline is one that is being asked more frequently.

For those pharmaceutical manufacturers that have yet to start the process or that are in the early stages of testing their patient information leaflets, the clock is ticking a lot faster than they may think. This feature looks at the processes that pharmaceutical companies need to be going through if they are to meet the July 1st, 2008 deadline. Surveys have revealed that people in the UK want more medicines information than they currently get (1), and that they value the PIL more highly than any source, other than doctors and pharmacists (2). But in the past, the vast majority of PILs, whilst factually correct, did not present the information in a way that the patient could easily understand. European Law currently states:

“The package leaflet shall reflect the results of the consultations with the target patient groups to ensure that it is legible, clear and easy to use (3). The results of assessments carried out in cooperation with target patient groups shall also be provided to the competent authority (4)”.

Whilst improving PILs is something we are all now committed to, actually achieving this goal (and the cost of doing so) is something that is falling at the feet of those involved in the manufacture and marketing of pharmaceutical products.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
After graduating from the University of London, Sophie Hobson earned a place on a graduate scheme working in a regulatory consultancy. Having joined TRAC Services, she developed her knowledge and experience to create a readability and user testing service for the company to provide to its clients. As a result of this work Sophie researched, designed and developed a testing programme which was launched earlier this year and which she now manages full time.
spacer
Sophie Hobson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drug’s manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement